Tocagen Shares Plummet On Failed Late-Stage Brain Cancer Study

Tocagen Shares Plummet On Failed Late-Stage Brain Cancer Study

Tocagen Inc TOCA shares were tumbling to an all-time low Thursday following an adverse clinical trial readout. 

Tocagen, a thinly traded nano-cap biotech, said Thursday morning a Phase 3 TOCA 5 study evaluating Toca 511 and Toca FC in patients with recurrent, high-grade glioma undergoing resection missed the primary endpoint of overall survival compared to the standard of care.

The Toca 511-Toca FC combination achieved median overall survival of 11.1 months compared to 12.2 months for the standard of care.

Toca 511 is a gene therapy delivered via a vector, and Toca FC is a prodrug that converts into an anticancer therapy.

The secondary endpoints also did not show meaningful difference between the arms of the trial, the company said.

The safety, tolerability and adverse event profile of the combo was as expected for this patient population, according to Tocagen. 

Recurrent brain cancer has very few treatment options and therefore there is a high unmet medical need.

"While the Toca 5 trial results are disappointing, we will be conducting a thorough analysis of the data including molecular analyses and pre-planned subgroups," Tocagen CEO Marty Duvall said in a statement. 

The company also said it will conduct an operational review.

Tocagen shares were plunging 81.58% to 77 cents at the time of publication in Thursday's premarket session.

Related Links:

The Daily Biotech Pulse: Ardelyx Awaits Ruling On Constipation Drug, Double Dose Of Good News For Roche, Tocagen Flunks Brain Cancer Study

Biotech Stock On The Radar: Aimmune Awaits Adcom Test

Posted In: BiotechNewsTop StoriesTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.